Abbott Receives FDA Emergency Use Authorization and Launches Test to Detect Novel Coronavirus

Company scaling up production at its U.S. manufacturing location

20-Mar-2020 - Abbott announced that the U.S. Food and Drug Administration has issued Emergency Use Authorization (EUA) for the company's molecular test for novel coronavirus (COVID-19). Abbott is immediately shipping 150,000 Abbott RealTime SARS-CoV-2 EUA tests to existing customers in the U.S. The tests are ...

Abbott Receives CE Mark for New Hepatitis Test

New Highly Sensitive Hepatitis Test Detects Mutant Virus Strains

11-Nov-2011 - Abbott announced it has received CE Marking (Conformité Européenne) in the European Union to market a new, highly sensitive diagnostic test for detection of hepatitis B surface antigen (HBsAg). The test is performed on Abbott's ARCHITECT® system. HBsAg assays may be used to help identify acute ...

Abbott to Fund Pharmaceutical and Diagnostics Research at the Weizmann Institute of Science

30-Jun-2011 - Abbott and Yeda Research and Development Company Ltd., the commercial arm of the Weizmann Institute of Science (WIS), have signed a three-year agreement in which Abbott will fund research programs at the Weizmann Institute of Science in selected health care fields.The collaboration will explore ...

Abbott Honored as a Great Place to Work Across Europe

Great Place to Work Institute Europe Names Abbott One of the Best Workplaces in Europe

21-May-2010 - The Great Place to Work® Institute named Abbott one of the Best Workplaces in Europe at its European Conference in Madrid. The company was specifically honored for workplace leadership in Denmark, Ireland and Norway. "Being named one of the Best Workplaces in Europe is a tremendous honor for ...

Abbott Completes Acquisition of STARLIMS Technologies

24-Mar-2010 - Abbott announced that it has completed its $123 million acquisition of STARLIMS Technologies Ltd. The acquisition provides Abbott with products and expertise to build its position in laboratory informatics "STARLIMS gives us access to innovative technologies and technical expertise for our ...

Abbott Receives European Regulatory Approval for New Ovarian Cancer Diagnostic Test

Abbott announces CE Mark (Conformite Europeene) certification for the ARCHITECT human epididymis protein 4 (HE4) test

19-Jan-2010 - A new diagnostic tool, which studies show can aid in determining the risk of whether a pelvic mass is benign or malignant, is now available in Europe. This simple blood test is expected to help in the assessment of epithelial ovarian cancer. This immunoassay is the first automated HE4 test ...

Abbott to Acquire Solvay Pharmaceuticals Business

Diversifies Abbott's pharmaceutical products, expanding international growth platform

01-Oct-2009 - Abbott announced a definitive agreement with the Solvay Group for Abbott to acquire Solvay's pharmaceuticals business for EUR 4.5 billion(US$6.6 billion) in cash, providing Abbott with a large and complementary portfolio of pharmaceutical products and a significant presence in key global emerging ...

Epigenomics AG and Abbott Molecular Inc. Expand Strategic In Vitro Diagnostics Partnership

20-Nov-2008 - Epigenomics AG and Abbott Molecular Inc. have expand their non-exclusive strategic partnership and amended their collaboration and license agreement in molecular diagnostics closed on September 25, 2007 accordingly. Under the amended agreement Abbott obtains additional non-exclusive commercial ...

Epigenomics AG: strategic in vitro diagnostics partnership with Abbott Molecular

27-Sep-2007 - Collaboration focuses on development and global commercialization of a molecular diagnostic test for the early detection of colorectal cancer. Abbott obtains non-exclusive worldwide rights to Epigenomics' proprietary DNA methylation biomarker Septin 9 Anticipate European market launch in 2009; ...

Agilent Technologies Obtains Multicolor, CGH Microarray Licenses from Abbott Molecular

08-Sep-2006 - Agilent Technologies Inc. announced it has obtained worldwide, non-exclusive patent licenses from Abbott Molecular Inc. for the manufacture, marketing and sale of oligonucleotide microarrays using a two-or-more color technology for gene expression and comparative genomic hybridization (CGH) ...